The trial, which will be conducted in healthy male volunteers, is a combined single and multiple ascending dose safety, tolerability and pharmacokinetic trial.
The company expects to evaluate around 32 subjects for a period of 14 days at four different dose levels.
Vernalis CEO Ian Garland said V81444’s progression into Phase I is an important milestone for Vernalis as they continue to study this potentially high value development programme.
"The A2A target has already been validated in other Parkinson’s disease programmes and this Phase I study is the first step in establishing the safety and pharmacokinetic profile of our A2A programme," Garland said.